How to buy stocks in Inovio Pharmaceuticals
- Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – INO – and research it before deciding if it's...
Full Answer
Should you invest in Inovio stock?
Keep in mind, however, that despite its high-reward potential, investing in Inovio stock is about as risky as it gets. If you don't have that kind of appetite, consider these much safer biotech stocks instead.
What companies does Inovio work with?
The Company's partners and collaborators include University of Pennsylvania, National Microbiology Laboratory of the Public Health Agency of Canada, NIAID, Merck, ChronTech, University of Southampton, and HIV Vaccines Trial Network. Inovio Pharmaceuticals, Inc. is headquartered in Blue Bell, Pennsylvania.
Is Inovio Pharmaceuticals (Ivo) stock overvalued?
Valuation metrics show that Inovio Pharmaceuticals, Inc. may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors.
What's the status of Inovio's ino-4800 vaccine?
Right now, the company's experimental vaccine is undergoing phase 2 trials. Inovio anticipates bringing INO-4800 to phase 3 during the second quarter of the year. The Department of Defense is fully funding both trials.
When does Inovo Pharmaceuticals stock expire?
INOVIO Pharmaceuticals Stock History. June 1, 2020, started by offering investors new options as they wait for the July 10, 2020 expiration date. The INO stocks have been going up since March 2020. The stocks have experienced occasional dips in the last 5 months.
What is a bid on Inovo Pharmaceuticals?
The bid is the price at which you want to buy the stock. If INOVIO Pharmaceuticals has a price of $23 and your bid price is $22, your order will only be fulfilled if the stock quote drops to that value.
What is limit order in stocks?
A limit order lets you trade stocks at a specific price. You can set the limit price of INOVIO at $22 and unless the stock quote reaches that price, the trade will not be executed.
What is an ask price in Inovo?
The ask is the price at which you want to sell the stock. If INOVIO has a price of $23 and you set an ask price of $25, your order will only be fulfilled if the stock quote rises to that value.
How long has Inovo kept patients alive?
INOVIO has kept many patients suffering from Glioblastoma alive for 1 year by combining treatment with Regeneron. The treatment involves using INOVIO’s drug INO-5401 and Regeneron drug known as Libtayo. INOVIO CEO J. Joseph Kim stated that the company would need more funding to reach its target market.
Does the stock market have more buyers or sellers?
If a stock market has more buyers than sellers, it’s only natural that the company’s stock price will climb. And if the company has more sellers than buyers of its stocks, the price will drop.
Is the INO-4800 still in the preclinical stage?
Its COVID-19 vaccine, INO-4800, is still in the preclinical test stage. Trade Smarter (Includes Benzinga Research) Start in 4 Minutes. Trade Smarter (Includes Benzinga Research) Seize opportunity no matter where you are with our Android and iPhone mobile apps.
The pharmaceutical company remains a step behind coronavirus vaccine leaders -- in funding and in the clinical trial timeline
Adria Cimino grew up with her nose in a book and a love of storytelling. By a twist of fate, she started her career writing about biotech in Boston and discovered that each company is the source of many fascinating stories.
Who's at the front of the pack?
From a timeline perspective, Inovio is not in the lead. Nine rival programs have moved into phase 2 or phase 3 trials. Moderna ( NASDAQ:MRNA) and AstraZeneca ( NASDAQ:AZN), which have both started phase 3, are among those closest to the finish line. Inovio plans to begin a phase 2/3 study in September.
So what does the trial data show?
Inovio stock was flying high, with gains of as much as 717% this year -- until it announced data from its phase 1 study. Shares have lost about 50% since those results were released June 30.
No love yet from the government
Operation Warp Speed -- the U.S. government's effort to help bring a vaccine to market by January -- has awarded billions of dollars to clinical-stage biotech companies such as Novavax ( NASDAQ:NVAX) and big pharma players like AstraZeneca. They received $1.6 billion and $1.2 billion, respectively.
What else is in the pipeline?
Though all eyes are on coronavirus vaccine candidates these days, long-term investors should look to Inovio's entire pipeline before deciding whether to buy the shares. Inovio is still in the clinical stage, but it does have a program beyond coronavirus that may be close to market.
What does this mean for investors?
All clinical-stage companies working on a coronavirus vaccine represent risk. If the program fails, they don't have other products that can immediately generate revenue. In my book, the fact that Inovio lags behind peers in funding and hasn't yet provided more detailed trial data increases the risk.
Inovio Pharmaceuticals (INO)
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Inovio Pharmaceuticals, Inc. - Buy
Zacks' proprietary data indicates that Inovio Pharmaceuticals, Inc. is currently rated as a Zacks Rank 2 and we are expecting an above average return from the INO shares relative to the market in the next few months. In addition, Inovio Pharmaceuticals, Inc.
Style Scorecard
The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.
Chart for INO
Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases.
There's an easy and emphatic answer
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights
Why Inovio sizzled
To answer the question, it's important to first understand exactly why Inovio's shares have delivered such a strong performance in 2020. There's one clear reason: COVID-19.
Signs of a fizzle?
The sizzling share price gains of the first half of the year began to wane after Inovio announced interim results from its phase 1 study of INO-4800. Inovio reported that 94% of participants in the early stage study demonstrated immune responses at week six after receiving two doses of INO-4800.
Not too late
Let's return to the original question: Is it too late to buy Inovio stock? I think the answer is an unequivocal no.
Signals & Forecast
Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development.
Support, Risk & Stop-loss
There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.
Is Inovio Pharmaceuticals stock A Buy?
Inovio Pharmaceuticals holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
Insiders are neutral selling more shares than they are buying in Inovio Pharmaceuticals
In the last 100 trades there were 1.12 million shares bought and 1.25 million shares sold. The last trade was done 37 days ago by Benito Simon X who sold 2 thousand shares. In general the insiders are selling more stocks than they buy. There can be a variety of reasons for this, but in general it can be considered as a negative signal.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
Who's at The Front of The Pack?
So What Does The Trial Data Show?
- Inovio stock was flying high, with gains of as much as 717% this year -- until it announced data from its phase 1 study. Shares have lost about 50% since those results were released June 30. INO data by YCharts What went wrong? Investors were disappointed that the company didn't reveal more details regarding neutralizing antibodies. This type of antibody is seen as a key ele…
No Love Yet from The Government
- Operation Warp Speed -- the U.S. government's effort to help bring a vaccine to market by January -- has awarded billions of dollars to clinical-stage biotech companies such as Novavax ( NVAX-3.58% )and big pharma players like AstraZeneca. They received $1.6 billion and $1.2 billion, respectively. So far, though, Operation Warp Speed hasn't offered Inovio any such award. This m…
What Else Is in The Pipeline?
- Though all eyes are on coronavirus vaccine candidates these days, long-term investors should look to Inovio's entire pipeline before deciding whether to buy the shares. Inovio is still in the clinical stage, but it does have a program beyond coronavirus that may be close to market. The company is set to report phase 3 data in the fourth quarter for...
What Does This Mean For Investors?
- All clinical-stage companies working on a coronavirus vaccine represent risk. If the program fails, they don't have other products that can immediately generate revenue. In my book, the fact that Inovio lags behind peers in funding and hasn't yet provided more detailed trial data increases the risk. Still, I wouldn't be surprised if Inovio shares climb in the coming months. Any positive news …